FOXO:NYE-FOXO Technologies Inc. (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 0.19

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.14M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

N/A

USD 10.78B
DOCS Doximity Inc

N/A

USD 7.70B
WEAV Weave Communications Inc

N/A

USD 0.89B
AMWL American Well Corp

N/A

USD 0.14B
MPLN MultiPlan Corporation

N/A

USD 0.12B
OWLT Owlet Inc

N/A

USD 0.07B
PHR Phreesia Inc

N/A

N/A
VEEV Veeva Systems Inc Class A

N/A

N/A
EVH Evolent Health Inc

N/A

N/A
TDOC Teladoc Inc

N/A

N/A

ETFs Containing FOXO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 494.31% 80% B- 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 494.31% 80% B- 96% N/A
Trailing 12 Months  
Capital Gain 79.92% 60% D- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.92% 60% D- 91% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -44.77% N/A N/A N/A F
Dividend Return -44.77% N/A N/A N/A F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.68% N/A N/A 20% F
Risk Adjusted Return -98.01% N/A N/A 1% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector